

JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: T -210J, Shahpur Jat, New Delhi -110049 (India)
 FAX: 0091- 11- 26498341, 26494708 Phone: 0091-11-26494519-24
 CIN No:- L74899DL1978PLC009181

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND TWELVE MONTHS ENDED MARCH 31, 2022

(Rs. In lakhs)


Sl. No.	Particulars	Quarter ended			12 Months Year ended	12 Months Year ended
		31.03.2022	31.03.2021	31.12.2021	31.03.2022	31.03.2021
		Audited	Audited	Unaudited	Audited	Audited
1	Revenue from operations					
	a) Net sales / income from operations	5,213.55	4,283.65	5,447.39	22,609.67	18,794.56
	b) Other operating Income	-	-	-	-	-
	Total revenue from operations	5,213.55	4,283.65	5,447.39	22,609.67	18,794.56
2	Other Income	27.57	266.05	195.36	333.60	439.33
3	Total Income [1+2]	5,241.12	4,549.70	5,642.75	22,943.27	19,233.89
4	Expenses					
	a) Cost of materials consumed	178.36	1,159.70	1,567.72	4,041.88	3,863.45
	b) Purchases of stock-in-trade	1,237.30	1,114.36	1,336.20	4,975.44	3,686.19
	c) Changes in Inventories of finished goods, work-in-progress and stock in trade	981.58	(768.30)	(730.55)	561.12	527.97
	d) Employee benefits expense	1,407.47	1,117.14	1,513.19	5,767.52	5,398.12
	e) Finance costs	5.82	13.01	5.81	28.51	51.35
	f) Depreciation and amortisation expense	64.50	26.26	37.01	152.62	108.60
	g) Other expenses	1,346.07	1,150.22	1,199.70	4,684.27	3,410.98
	Total expenses	5,221.10	3,811.39	4,929.08	20,211.36	17,046.66
5	Profit before exceptional Items and taxes (3-4)	20.02	738.31	713.67	2,731.91	2,187.23
6	Exceptional Items	-	-	-	-	-
7	Profit before tax [5-6]	20.02	738.31	713.67	2,731.91	2,187.23
8	Tax expense	17.52	228.41	173.02	773.21	481.40
9	Profit after tax [7-8]	2.50	509.90	540.65	1,958.70	1,705.83
10	Other comprehensive Income					
	a) (i) Items that will not be classified to profit or loss	191.62	21.39	-	191.62	21.39
	(ii) Income tax relating to items that will not be reclassified to profit and loss	(55.80)	(6.23)	-	(55.80)	(6.23)
	Total other comprehensive income [A(I) + A(II)]	135.82	15.16	-	135.82	15.16
11	Total comprehensive income [9+10]	138.32	525.06	540.65	2,094.52	1,720.99
12	Paid up equity share capital (face value Rs. 5/- each)	1,309.90	1,309.90	1,309.90	1,309.90	1,309.90
13	Earnings per equity share (face value Rs 5/- each)					
	a) Basic (Rs.)	0.01	1.95	2.06	7.48	6.51
	b) Diluted (Rs.)	0.01	1.95	2.06	7.48	6.51



JAGSONPAL PHARMACEUTICALS LIMITED
 Regd. Office: T -210J, Shahpur Jat, New Delhi -110049 (India)
 FAX: 0091- 11- 26498341, 26494708 Phone: 0091-11-26494519-24
 CIN No:- L74899DL1978PLC009181
Statement of Assets and Liabilities

(Rs in lakhs)

PARTICULARS	As at 31.03.2022	As at 31.03.2021
	Audited	Audited
ASSETS		
Non-current assets		
a) Property , Plant and Equipment	2,237.29	2,334.66
b) Capital Work-in-Progress	-	-
c) Goodwill	3.00	3.00
d) Intangible assets	234.53	234.53
e) Financial assets		
i) Investments		
(i) Investments	2,057.55	1,205.84
(ii) Loans	-	-
(iii) Other	-	28.61
f) Non-current tax assets (net)	943.12	457.76
g) Other non-current assets	292.26	108.13
Total - Non-current assets	5,767.75	4,372.53
Current assets		
a) Inventories	2,974.21	2,972.45
b) Financial assets		
(i) Investments	2,214.13	325.07
(ii) Loans	30.51	26.77
(iii) Trade receivables	1,557.74	1,266.40
(iv) Cash and cash equivalents	2,602.93	5,894.29
(v) Bank balances other than (iv) above	12.43	128.69
(vi) Other	1.27	25.03
c) Other current assets	1,684.50	1,409.01
Total - Current assets	11,077.72	12,047.71
TOTAL - ASSETS	16,845.47	16,420.24
EQUITY AND LIABILITIES		
EQUITY		
a) Equity share capital	1,309.90	1,309.90
b) Other equity	11,775.66	10,883.01
Total - Equity	13,085.56	12,192.91
LIABILITIES		
Non-current liabilities		
a) Provisions	125.65	1.80
b) Deferred tax liabilities (Net)	218.74	185.86
Non-current liabilities	344.39	187.66
Current Liabilities		
a) Financial Liabilities		
(i) Borrowings	-	678.79
(ii) Trade payables	1,628.62	1,804.99
(iii) Other financial liabilities	549.12	438.25
b) Provisions	49.01	84.68
c) Current tax liabilities	796.13	382.15
d) Other current liabilities	392.64	650.81
Total current liabilities	3,415.52	4,039.67
Total - LIABILITIES	3,759.91	4,277.33
TOTAL - EQUITY AND LIABILITIES	16,845.47	16,420.24



Notes:


- 1) The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 30th May, 2022.
- 2) In line with the provisions of Ind AS 18 , the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
- 3) Figures for the previous periods have been regrouped , wherever necessary, to correspond with the figures of the current period.
- 4) The above results are available on website of the company www.jagsonpal.com and on the Website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
- 5) The Company has adopted Ind AS from April 1, 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder.
- 6) Provision for taxation includes provision for current tax.
- 7) The company has proposed and paid Interim dividend of INR 4 per Equity share of Face Value of INR 5/- each (i.e. 80%).
- 8) Figures for the quarter ended 31st March 2022 are balancing figures between the audited figures in respect of full financial year ended 31st March 2022 and published figures upto 3rd Quarter ended 31st December 2021.

Place : New Delhi
Date : 30th May 2022



By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
Managing Director
DIN No 00059492



Jagsonpal Pharmaceuticals Limited
Standalone Cash flow statement for the period ended 31 March 2022
(All amounts in Indian Rupees lacs, unless stated otherwise)

	For the year ended 31st March 2022	For the year ended 31 March 2021
A. Cash flow from operating activities		
Net Profit before tax	2,731.91	2,187.23
Other Comprehensive Income	135.82	15.16
Depreciation and amortisation expense	152.62	108.60
Loss/ (profit) on sale of property, plant and equipment	(8.51)	-
Interest income	(154.56)	(299.24)
Interest expense	28.51	51.35
Prepaid Expense	-	12.96
Fair value gain on financial instruments at fair value through profit or loss	104.08	25.05
Deferred tax liability reduced	32.88	(123.30)
Operating profit before working capital changes	3,022.75	1,977.81
Movements in working capital:		
Decrease / (increase) in trade receivables	(291.34)	878.94
Decrease / (increase) in inventories	(1.76)	(39.95)
(Decrease) / (increase) in other financial assets	48.63	(3.93)
Decrease / (increase) in other assets	(459.61)	(973.70)
(Decrease) / increase in trade payables	(176.36)	634.06
(Decrease) / increase in provisions	88.19	86.48
(Decrease) / increase in other financial liabilities	(567.92)	85.97
(Decrease) / (increase) in tax assets	264.64	1,194.80
(Decrease) / increase in tax liabilities	(359.23)	(929.22)
(Decrease) / increase in other liabilities	(258.18)	225.98
Cash generated from operations	1,309.81	3,137.24
Income Tax paid	(750.00)	(315.00)
Net cash flow from operating activities (A)	559.81	2,822.24
B. Cash flow from investing activities		
Net of Sale/ Purchase of property, plant and equipment and intangible assets (including capital work-in-progress)	(46.75)	(46.91)
Purchase of investments	(2,844.86)	(417.28)
Interest received	270.82	237.76
Net cash (used in) / from investing activities (B)	(2,620.79)	(226.43)
C. Cash flow from financing activities		
Interest paid	(28.51)	(51.35)
Change in Equity	(153.95)	(369.47)
Dividend	(1,047.92)	(262.00)
Net cash from/ (used in) financing activities (C)	(1,230.38)	(682.82)
Net increase/(decrease) in cash and cash equivalents (A+ B+C)	(3,291.36)	1,912.99
Effect of exchange differences on cash and cash equivalents held in foreign currency	-	-
Cash and cash equivalents at the beginning of the year	5,894.29	3,981.30
Cash and cash equivalents at the end of the year	2,602.93	5,894.29
Components of cash and cash equivalents		
Cash in hand	89.40	31.14
With banks	2,513.53	5,863.15
Total cash and cash equivalents (Note 13)	2,602.93	5,894.29
Summary of significant accounting policies		

2

The accompanying notes form an integral part of the financial statements
As per our report of even date

For H.L. Bansal and CO.
Chartered Accountants.
FRN. NO. 008563N

Hira Lal Bansal
Partner
M.No. 086990

Place: Delhi
Date: 30.05.2022

For and on behalf of the Board of Directors,
For Jagsonpal Pharmaceuticals Limited.

R.P.S Kochhar
DIN 00059492
Chairman & Managing Director

SV Subha Rao
Chief Financial Officer

Nandita Singh
Company Secretary